Global

CSL Behring Submits NDS to Health Canada Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema

Pivotal phase II/III study demonstrates C1-INH is effective treatment for acute HAE attacks

Toronto, Ontario — 17 April 2008

CSL Behring has filed a new drug submission (NDS) with Health Canada seeking approval to market its C1-esterase inhibitor concentrate in Canada for the treatment of hereditary angioedema (HAE), a rare and serious genetic disorder. The submission is based on the recently completed phase II/III prospective, double-blind placebo-controlled International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T.), the largest HAE trial ever conducted, that studied the efficacy of pasteurized C1-INH concentrate.

The proposed indications are for:

  • the treatment of acute episodes of HAE and;
  • pre-operative prophylaxis to prevent HAE-associated complications during or after a procedure.
  • Currently, there are no specifically approved therapies for HAE in North America. CSL Behring recently filed a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for C1-INH.

"Our submission to Health Canada for marketing approval of C1-INH is an important step in CSL Behring’s pursuit to meet the unmet need of hereditary angioedema patients for a therapy that will treat acute attacks of this potentially life-threatening disorder," said Val Romberg, Senior Vice President of Research and Development at CSL Behring. "We are confident that our expertise in developing and manufacturing plasma-derived protein therapies will be advantageous in our pursuit of approval in Canada."

HAE is a genetic disorder caused by a deficiency of C1-INH which is inherited in an autosomal dominant manner. Symptoms include episodes of edema or swelling in the hands and feet, the face, the abdomen, and/or the larynx. Patients who have abdominal attacks can experience episodes of severe pain, diarrhea, nausea, and vomiting caused by swelling of the intestinal wall. Attacks that involve the face and larynx can result in airway closure, asphyxiation, and, if untreated, death. Diagnosis of HAE requires a blood test to confirm low or abnormal levels of C1-INH. There are estimates HAE occurs in 1 in 10,000 to 1 in 50,000 people worldwide.

The submission which will be the subject of review by Health Canada is mainly based on a study of 124 HAE patients with acute, moderate, or severe abdominal or facial attacks. C1-INH concentrate was administered at two different doses and compared to placebo. The main study endpoints were: time to onset of symptom relief from HAE attacks, proportion of subjects with worsening clinical HAE symptoms, and safety. Results showed patients receiving C1-INH concentrate had a median time to symptom relief of 30 minutes, versus 90 minutes for patients receiving placebo, (p=0.0025). Additionally, the proportion of subjects with worsening HAE symptoms after receiving treatment was significantly lower in the C1-INH P 20 U/kg treated group (p= 0.001).

CSL Behring manufactures and sells C1-INH concentrate in Germany, Austria, Switzerland, and several other countries under the trade name Berinert® P.

About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.

Media Contacts:
Sheila A. Burke, Director, Communications & Public Relations
Worldwide Commercial Operations
CSL Behring
610-878-4209 (o)
484-919-2618 (c)
Sheila.Burke@cslbehring.com

Brian Thompson
MCS
908-234-9900 (o)
201-952-5967 (c)
briant@mcspr.com

Share
LinkedIn Twitter Facebook Google+